PL Growth
PL Growth
批准号:
8934261
负责人:
TONY R. HUNTER
金额:
$1.97万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-12-01 至 2018-11-30
关键词:
AdenovirusesAffectAmino AcidsAntimitotic AgentsApoptoticAreaBRCA1 geneBiologyBudgetsCancer BiologyCancer CenterCancer Center Support GrantCell AgingCell CycleCell Cycle CheckpointCell Differentiation processCell NucleusCell ProliferationCell SizeCellsChromatinChromosomesClinicalDNA DamageDNA damage checkpointDevelopmentDirect CostsEnsureFunctional disorderFundingGene ExpressionGenomeGenome StabilityGenomic InstabilityGenomicsGoalsGrantGrowthHeterogeneityHistonesHomeostasisHuman ResourcesKnock-in MouseLaboratoriesLightMaintenanceMalignant NeoplasmsMammary glandMediatingMethodsMitosisMitoticModificationMolecularMutationNematodaNuclear PoreNuclear Pore Complex ProteinsNuclear ReceptorsNucleic Acid Regulatory SequencesOncogenicOncolyticPathway interactionsPeer ReviewPharmaceutical PreparationsPlayProcessProtein p53ProteinsPublicationsRegulationRepressionResearchResearch Project GrantsResistanceRoleRuptureSignal PathwaySignal TransductionSomatic CellStem cellsStressSuppressor GenesSystemTelomeraseTherapeuticTrans-ActivatorsTranscriptional RegulationTranslationsTumor Suppressor GenesTumor Suppressor ProteinsUnited States National Institutes of HealthYeastsbiological adaptation to stresscancer cellcancer stem cellcancer therapycancer typecell growthcell typechemical geneticschemotherapychromatin modificationcrosslinkfetalgene inductionhistone modificationin vivointerestmalignant breast neoplasmmembermicronucleusmouse modelmutantneoplastic cellprogramsrepairedresponsestemtelomeretumortumor progression
中文摘要
生长控制和基因组稳定性计划的总体科学目标是了解
增殖机制、致癌信号通路的转录调节、DNA损伤
反应和检查点激活,维持基因组完整性和端粒功能,以及这些
过程在癌细胞中被破坏或改变。基因组的不稳定性是导致
癌症进展和肿瘤异质性的发生,并可产生敏感性或耐药性
靶向和致损性癌症疗法。该计划的成员研究如何不同的方面
正常的体细胞、干细胞和癌细胞对DNA损伤作出反应,维持基因组的完整性,
对传统和靶向化疗有反应。p53在细胞周期检查点调控中的作用
在不同的应激反应中,以及使用腺病毒早期蛋白来询问细胞信号传导途径
和p53检查点信号传导包括该计划的重要重点领域,
翻译.化学遗传学被用于研究驱动癌细胞的细胞信号通路
增殖其他重要的主题包括致癌基因转录调控的分子机制,
途径和肿瘤抑制基因表达,核孔亚基如何调节基因表达,
以及乳腺癌中胎儿乳腺干细胞与干细胞样细胞的关系。
该计划包括来自五个不同实验室(部门)的九名成员,见下一页
人员名单
上一个预算年度的NCI和其他同行评审的癌症相关支持(直接成本)为
304万9383美元美国国立卫生研究院和其他联邦机构对该项目的实质性支持见
外部资助的研究项目。
在上一个资助期(2008年至2010年),本计划成员发表的癌症相关出版物总数
2012年,132。在所有出版物中,1%为方案内出版物,13%为方案间出版物。
英文摘要
The overall scientific goal of the Growth Control and Genomic Stability Program is to understand
mechanisms of proliferation, transcriptional regulation of oncogenic signaling pathways, DNA damage
response and checkpoint activation, maintenance of genomic integrity and telomere function, and how these
processes are disrupted or altered in cancer cells. Genomic instability is one of the key contributors to
cancer progression and the genesis of tumor heterogeneity, and can engender either sensitivity or resistance
to targeted and dastogenic cancer therapies. The members of this program study diverse aspects of how
normal somatic cells, stem cells, and cancer cells respond to DNA damage, maintain genomic integrity, and
respond to traditional and targeted chemotherapies. The functions of p53 in cell cycle checkpoint control and
in diverse stress responses, and the use of adenovirus early proteins to interrogate cell signaling pathways
and p53 checkpoint signaling comprise areas of significant focus of the program with opportunities for clinical
translation. Chemical genetics is being used to study cellular signaling pathways that drive cancer cell
proliferation. Other important topics include molecular mechanisms of transcriptional regulation of oncogenic
pathways and of tumor suppressor gene expression, how nuclear pore subunits regulate gene expression,
and the relationship of fetal mammary stem cells to stem-like cells in breast cancer.
The program includes nine members from five different Laboratories (Departments), see the following page
for a list of personnel.
The NCI and other peer-reviewed cancer related support (direct costs) for the last budget year was
$3,049,383. The substantial NIH and other federal support for this program is outlined in the table of
externally funded research projects.
The total number of cancer-relevant publications by members of this program in the last grant period (2008-
2012) was 132. Of the total publications, 1% were intraprogrammatic and 13% were interprogrammatic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative and Biostatistics Core
-
批准号:10629066
-
项目类别:
-
资助金额:$22.79万
-
财政年份:2023
-
负责人:TONY R. HUNTER
-
依托单位:
Overcoming mechanisms of therapeutic resistance in pancreatic ductal adenocarcinoma
-
批准号:10629062
-
项目类别:
-
资助金额:$295.32万
-
财政年份:2023
-
负责人:TONY R. HUNTER
-
依托单位:
Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
-
批准号:10629064
-
项目类别:
-
资助金额:$49.76万
-
财政年份:2023
-
负责人:TONY R. HUNTER
-
依托单位:
Histidine phosphorylation as a new target for cancer therapy
-
批准号:10680390
-
项目类别:
-
资助金额:$113.13万
-
财政年份:2019
-
负责人:TONY R. HUNTER
-
依托单位:
Histidine phosphorylation as a new target for cancer therapy
-
批准号:10228707
-
项目类别:
-
资助金额:$115.39万
-
财政年份:2019
-
负责人:TONY R. HUNTER
-
依托单位:
Histidine phosphorylation as a new target for cancer therapy
-
批准号:10020348
-
项目类别:
-
资助金额:$115.44万
-
财政年份:2019
-
负责人:TONY R. HUNTER
-
依托单位:
Histidine phosphorylation as a new target for cancer therapy
-
批准号:10450680
-
项目类别:
-
资助金额:$115.44万
-
财政年份:2019
-
负责人:TONY R. HUNTER
-
依托单位:
The Invisible Phosphoproteome: New Tools to Study Histidine Phosphorylation
-
批准号:9228357
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2015
-
负责人:TONY R. HUNTER
-
依托单位:
The Invisible Phosphoproteome: New Tools to Study Histidine Phosphorylation
-
批准号:9437683
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2015
-
负责人:TONY R. HUNTER
-
依托单位:
The Invisible Phosphoproteome: New Tools to Study Histidine Phosphorylation
-
批准号:9017975
-
项目类别:
-
资助金额:$44.38万
-
财政年份:2015
-
负责人:TONY R. HUNTER
-
依托单位:
Program Planning
-
批准号:8934262
-
项目类别:
-
资助金额:$1.73万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
SR Pep Syn
-
批准号:8934273
-
项目类别:
-
资助金额:$4.18万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
SR Trans
-
批准号:8934275
-
项目类别:
-
资助金额:$24.36万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
SR Pro
-
批准号:8934274
-
项目类别:
-
资助金额:$20.76万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
SR Gene Therapy
-
批准号:8934271
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
Senior Leadership
-
批准号:8934259
-
项目类别:
-
资助金额:$19.66万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
SR Adv Bio
-
批准号:8934267
-
项目类别:
-
资助金额:$22.69万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
Development Funds
-
批准号:8934265
-
项目类别:
-
资助金额:$55.03万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
PL Mouse
-
批准号:8934260
-
项目类别:
-
资助金额:$1.97万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
SR Fun Gen
-
批准号:8934270
-
项目类别:
-
资助金额:$22.31万
-
财政年份:2013
-
负责人:TONY R. HUNTER
-
依托单位:
海外基金